Abstract: A process for selectively producing monoclonal antibodies which comprises selectively bringing together proliferating cells and the appropriate B-cells by means of ligand recognition of respective cell surface receptors and then fusing together the proliferating cells and B-cells thus brought together.
Type:
Grant
Filed:
June 8, 1984
Date of Patent:
March 19, 1991
Assignee:
The Johns Hopkins University
Inventors:
Solomon H. Snyder, Mathew M. S. Lo, Tian Y. Tsong, Mary K. Conrad
Abstract: A method for the saccharification of a cellulosic material comprises the steps of culturing a microorganism of Acremonium cellulolyticus in a medium containing carbon sources and nitrogen sources, collecting a cellulolytic enzyme from the resultant culture broth, and causing the cellulolytic enzyme to act on the cellulosic material.
Type:
Grant
Filed:
February 5, 1987
Date of Patent:
September 11, 1990
Assignees:
Agency of Industrial Science & Technology, Ministry of International Trade & Industry
Abstract: Fish are cultured in one or more flumelike watercourses or "raceways" bounded by raceway-defining means. The water flow rate is such that the fish swim substantially continuously to maintain position. The fish are configured too closely to assert territorial rights, as they do when held at lower concentration. Water enters via a well enclosure at the upstream end, as by airlift upwelling; flows through the watercourse, sweeping waste materials along; and departs via a weir-like enclosure at the downstream end, where dissolved or undissolved waste is removed. Water is preferably supplied from and returned to a surrounding natural or man-made body of water, which also preferably floats the physical raceway means, facilitating water depth adjustment. Distribution of fish to adjacent raceways without any netting or handling conducive to injury is accomplished via airlift means. Fish so cultured remain healthy and grow rapidly and uniformly.
Type:
Grant
Filed:
November 22, 1988
Date of Patent:
April 10, 1990
Assignee:
Fisheries Engineering Research and Development Co., Inc.
Abstract: A synthetic structural gene encoding CTAP-III or CTAP-III-Leu21 including adaptors for the carboxy and amino terminal ends of the gene which contain start and stop codons and convenient restriction sites for use in cloning the gene is described. The gene was designed for efficient expression in bacteria and to include two unique restriction sites for BamHI and XbaI. Plasmid expression vectors that are derivatives of pBR322 that contain a ColE1 insert which includes the expression control sequence and structural gene for colicin are also described. Constructs for expressing CTAP-III, CTAP-III-Leu21, CTAP-III or CTAP-III-Leu21 having a nonpolar pentapeptide fused to its amino terminus, and fusion proteins of such CTAP-III proteins and a colicin fragment are prepared by inserting the synthetic structural gene into the vectors at positions in phase with the colicin expression control sequence and under the control thereof.
Abstract: Generating a human epithelium on a living animal by a method in which cultured human keratinocytes are placed in contact with the subdermal connective tissue of a non-human animal.
Type:
Grant
Filed:
June 19, 1987
Date of Patent:
December 19, 1989
Assignee:
President and Fellows of Harvard College
Abstract: A monoclonal antibody against GnRH and particularly designated USASK/DSIL-GnRH is produced by a hybrid formed by fusion of cells from a myeloma line and antibody producing cells of the immune system from an animal previously immunized with a source of GnRH; the monoclonal antibody has the following characteristics:(i) it produces a short term reduced mean level of luteinizing hormone (LH) in immunized mammals;(ii) it produces a short term reduced pulsatile secretion of LH in immunized mammals;(iii) it terminates pregnancy in a female mammal with an accompanying decline in progesterone levels;(iv) it produces a long term reduced testosterone level in a male mammal, and,(v) it induces inferility in a male mammal;thus passive immunization of the female or male with the monoclonal antibodies may be employed to reduce fertility and terminate pregnancy.
Type:
Grant
Filed:
May 15, 1987
Date of Patent:
November 7, 1989
Assignee:
University of Saskatchewan
Inventors:
David W. Silversides, Reuben J. Mapletoft, Bruce D. Murphy, Virkam Misra
Abstract: A panel of monoclonal antibodies produced from normal human lung fibroblasts and human lung tumors as immunogen is used to diagnose the presence of lung tumors and differentiate between those which are benign and those which are cancerous.
Type:
Grant
Filed:
August 10, 1987
Date of Patent:
September 12, 1989
Assignee:
Sloan-Kettering Institute for Cancer Research
Inventors:
Hans-Joachim Feickert, Wolfgang Rettig, Karen Chorney, Carlos Cordon-Cardo, Myron R. Melamed, Kenneth O. Lloyd, Herbert F. Oettgen, Lloyd J. Old, Bernd Anger
Abstract: A new continuous rabbit cell line, designated TP-3, and variants thereof, which are hypoxyxanthineguanine-phosphoribosyl transferase deficient, hypoxyxanthine-aminopterine-thymidine sensitive, fast growing and non-antibody producing, and the methods for preparing the TP-3 cell line. Also, rabbit-rabbit hybrid cells formed by fusing the TP-3 cell line with antibody-producing cells from immunized rabbits, which hybrid cells are hypoxyxanthine-aminopterine-thymidine insensitve and secrete rabbit antibodies, and the methods for preparing the hybrid cells and hybrid cell lines. The invention further comprises rabbit monoclonal antibody.
Type:
Grant
Filed:
May 3, 1985
Date of Patent:
August 22, 1989
Inventors:
Arthur D. Strosberg, Jean-Gerard Guillet
Abstract: A method of effectively producing antobodies by creating antibody-producing hybrid cell lines utilizing an established B cell line as a parent cell lines and fusing these B cells to normal, human antibody-producing cells. A preferred established B cell line for use in this invention consists of B cells characterized by the presence of immunoglobulin at their cell surface.
Abstract: Hybrid cell line for production of monoclonal antibody to an antigen found on approximately 70% of normal human thymocytes. The hybrid is formed by fusing splenocytes from immunized CAF.sub.1 mice with P3X63Ag8Ul myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.
Abstract: The present invention provides a novel method of treating a synthetic or naturally occurring implant, such as a vascular graft, intended for implantation in a human patient, comprising obtaining human microvascular rich tissue from that patient; separating microvascular endothelial cells from that tissue; and placing said microvascular endothelial cells onto said implant to provide at least about 50% confluence of said cells on the surface of said implant to be treated. In the preferred embodiment, the microvascular rich tissue is perinephric fat, which is obtained from the donor and subjected to a digestive separation process to provide an abundant supply of microvascular endothelial cells. In the preferred embodiment, these microvascular endothelial cells are placed onto the implant by suspending them in a protein (plasma) containing physiologic saline solution, which is incubated on the graft until the endothelial cells either adhere to the graft surface or clot within the protein solution.
Abstract: A method for eliminating turbidity in a biological fluid by combining said fluid with a surfactant and an enzyme is disclosed as well as a diagnostic reagent formulation for that purpose.
Type:
Grant
Filed:
August 26, 1986
Date of Patent:
March 28, 1989
Assignee:
Technicon Instruments Corporation
Inventors:
Shyun-long Yun, Luis P. Leon, Syed I. Ahmad
Abstract: The invention provides restriction endonuclease Mf1 I capable of recognizing the base sequence as shown below on a double-stranded DNA molecule and cleaving the DNA chain at the arrow-marked positions, but has no such action when A is methylated5'--Pu.dwnarw.GATC Py--3'3'--Py CTAG.uparw.Pu--5'(wherein A represents adenosine, G guanosine, T thymidine, C cytidine, Pu adenosine or guanosine, and Py thymidine or cytidine). The restriction endonuclease is produced by culturing Microbacterium flavum IAM 1642, FERM BP-938 in a culture medium and recovering it from the culture.
Abstract: Two novel hybridoma cell lines, ATCC #HB-8397 and ATCC #HB-8398 produce monoclonal antibody monospecific to a single determinant shared by a set of three closely related cytoplasmic antigens of Candida albicans. The antigens have molecular weights of 120-135 Kd, 48-52 Kd, and 35-38 Kd. The hybridomas are formed by fusing splenocytes from immunized BALB/c mice with SP2/O-Ag 14 myeloma cells. Monoclonal and monospecific, polyclonal antibodies to these cytoplasmic antigens find application in the immunodiagnosis of Candida infections.A procedure is provided for preparing partially purified cytoplasmic antigen of pathogenic Candida species for administration to splenocyte-donating mice. Also provided is a method for the biochemical purification of cytoplasmic antigen of a pathogenic Candida species used for the preparation of monoclonal and monospecific, polyclonal antisera thereto.
Type:
Grant
Filed:
March 30, 1987
Date of Patent:
February 21, 1989
Assignee:
Temple University of the Commonwealth System of Higher Education
Inventors:
Helen R. Buckley, Michael T. Largen, Nancy A. Strockbine
Abstract: Hybrid cell line for production of monoclonal antibody to an antigen found on normal human cytotoxic and suppressor T cells. The hybrid is formed by fusing splenocytes from immunized CAF.sub.1 mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.
Abstract: Hybrid cell line for production of monoclonal antibody to an antigen found on essentially all normal human T cells and on approximately 95% of normal human thymocytes. The hybrid is formed by fusing splenocytes from immunized CAF.sub.1 mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.
Abstract: The peptide X-Arg-Gly-Asp-R-Y wherein X is H or at least one amino acid and Y is OH or at least one amino acid, and R is an amino acid selected from Thr or Cys, or other amino acid, having the same cell-attachent activity as fibronectin and the peptide X-Arg-Gly-Asp-Ser-Y, wherein X and Y, having said activity are disclosed.
Abstract: Catalytic chemical and biochemical conversion reactions are carried out in a novel compartmentalized catalytic reactor which enables the energy-efficient coupling of the conversion reaction with various energy-consuming post-conversion operations. The catalytic reactor is compartmentalized by means of a multilayer composite membrane comprising a catalytic membrane layer and one or more permselective membrane layers. The arrangement and properties of the membrane layers are such as to enable the free energy change of the conversion reaction to be utilized as the required energy source for effecting various post-conversion operations, including product separation, recovery and enrichment, and second-stage catalytic conversions with unfavorable reaction equilibria.
Abstract: A serum-free animal tissue culture medium contains a mixture of six fatty acids and albumin or dextran. The medium is particularly adapted for the primary culture of rat liver epithelial cells and possibly in the presence of hormones and/or growth factors, for obtaining cell lines, in particular of myelomae and hybridomae.
Type:
Grant
Filed:
November 21, 1984
Date of Patent:
November 22, 1988
Assignee:
Institut National de la Sante et de la Recherche Medicale
Inventors:
Martina L. Chessebeuf, Prudent H. Padieu